- Home
- MPW vs MIRM Comparison
MPW vs MIRM Comparison
Compare MPW & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- MIRM
- Stock Information
- Founded
- MPW 2003
- MIRM 2018
- Country
- MPW United States
- MIRM United States
- Employees
- MPW N/A
- MIRM N/A
- Industry
- MPW Real Estate Investment Trusts
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- MIRM Health Care
- Exchange
- MPW Nasdaq
- MIRM Nasdaq
- Market Cap
- MPW 2.7B
- MIRM 2.5B
- IPO Year
- MPW 2005
- MIRM 2019
- Fundamental
- Price
- MPW $4.33
- MIRM $48.39
- Analyst Decision
- MPW Hold
- MIRM Strong Buy
- Analyst Count
- MPW 6
- MIRM 9
- Target Price
- MPW $5.67
- MIRM $66.22
- AVG Volume (30 Days)
- MPW 8.2M
- MIRM 463.0K
- Earning Date
- MPW 08-07-2025
- MIRM 08-06-2025
- Dividend Yield
- MPW 7.32%
- MIRM N/A
- EPS Growth
- MPW N/A
- MIRM N/A
- EPS
- MPW N/A
- MIRM N/A
- Revenue
- MPW $994,715,000.00
- MIRM $379,251,000.00
- Revenue This Year
- MPW N/A
- MIRM $35.83
- Revenue Next Year
- MPW $7.11
- MIRM $16.83
- P/E Ratio
- MPW N/A
- MIRM N/A
- Revenue Growth
- MPW 23.40
- MIRM 69.31
- 52 Week Low
- MPW $3.51
- MIRM $33.45
- 52 Week High
- MPW $6.55
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- MPW 35.86
- MIRM 50.61
- Support Level
- MPW $4.25
- MIRM $49.39
- Resistance Level
- MPW $4.55
- MIRM $51.93
- Average True Range (ATR)
- MPW 0.12
- MIRM 1.52
- MACD
- MPW 0.01
- MIRM -0.18
- Stochastic Oscillator
- MPW 19.77
- MIRM 14.49
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.